DR.WU (6523): Striving to Become Asia’s Leading Medical Skincare Brand
CDRC Corporate Development Research Center / Board Review
From a dermatology clinic in Taipei to Taiwan’s leading medical skincare brand, DR.WU founder and Chairman Wu Yi-Jui is advancing five key strategies, integrating environmental sustainability and artificial intelligence (AI) to position the company as Asia’s leading medical skincare brand.
In 2003, at just 26 or 27 years old, Wu initially wanted to ease the workload of his father, renowned dermatologist Dr. Wu Ying-Chun. This led to the unexpected founding of the DR.WU medical skincare brand.
In late 2004, Taiwanese celebrity Barbie Hsu (Big S) published her bestselling beauty book Beauty Queen, bringing DR.WU products into the spotlight. Two decades later, DR.WU has become Taiwan's leading medical skincare brand. The company was listed on Taiwan's over-the-counter market in 2016, and its market capitalization exceeded NT$8 billion as of June 2024.
In the first quarter of 2024, DR.WU achieved record-high earnings per share (EPS) of NT$3.60 for the same period, representing 59% year-on-year growth. This reflects the company's recovery from setbacks in mainland China and the COVID-19 pandemic. In an exclusive interview, Wu outlined five medium-term strategies to drive the company's next phase of growth.
Strategy 1: Market Expansion
"My dream has always been to make DR.WU Asia's No. 1 medical skincare brand," Wu said.
Despite losing several hundred million New Taiwan dollars in mainland China between 2015 and 2020, Wu firmly stated, "I will not give up on the mainland Chinese market."
Learning from past setbacks, DR.WU has adopted a direct-to-consumer (D2C) business model in mainland China, partnering with Yatsen E-Commerce, which owns several beauty brands, including Perfect Diary.
By eliminating inventory and direct retail operating costs, DR.WU now focuses on product shipments, turning annual losses of over NT$100 million into profits.
Meanwhile, during the early stages of the COVID-19 pandemic, DR.WU partnered with a small Japanese company to enter Japan's market through e-commerce platforms, including Rakuten, Amazon Japan, and Qoo10.
Japan has since become DR.WU's most promising overseas market. Wu noted that Northeast Asia will be the company's next major focus, with plans to enter South Korea after establishing a stronger presence in Japan.
Based on its experience in mainland China, DR.WU now works exclusively with distributors in overseas markets outside Taiwan. Wu explained that this model effectively reduces sales costs while building three-way partnerships among DR.WU, distributors, and retail channels to achieve mutual benefits.
The company will also continue expanding into Southeast Asian markets.
Strategy 2: Product Diversification
"I have always insisted that DR.WU maintain its core identity as a professional dermatology brand," Wu emphasized when discussing the company's product diversification strategy.
While DR.WU previously focused primarily on facial skincare, the company plans to expand into body care, hair care, and health supplements. Leveraging its dermatological expertise, DR.WU aims to accelerate new product development.
Currently, DR.WU launches approximately ten new products annually, or 15 to 20 when upgraded products are included.
Wu has instructed the R&D team to speed up development, adding that beauty-from-within products will also be among DR.WU's future priorities.
Strategy 3: Brand Diversification
After 20 years in business, DR.WU has built an increasingly diverse customer base. Growing alongside consumers and meeting their changing needs are central to Wu's multi-brand strategy.
Wu explained that, as he approaches 50, customers who began using DR.WU products 20 years ago are now becoming more concerned about anti-aging.
To meet these evolving needs, DR.WU launched its second brand, re’dermx, in 2021, officially entering the anti-aging and preventive medicine markets.
Wu is also considering mergers and acquisitions to expand the company's brand portfolio, with opportunities extending beyond Taiwan.
He noted that two professional physician-founded skincare brands in Japan had already been acquired by major corporations, highlighting the potential for similar opportunities.
Strategy 4: Sustainability and Clean Beauty
High Efficacy and Low Sensitivity have always been DR.WU's core technical values. Wu now plans to integrate a third principle: Sustainable Clean Beauty.
He believes that today's medical skincare consumers are increasingly concerned about environmental protection. While pursuing personal beauty, they also want to minimize their impact on the environment.
To support this vision, DR.WU has introduced three sustainability initiatives:
WU Clean: Product purity and safety
WU Care: Social responsibility and community care
WU Green: Environmental protection and sustainability
Beyond incorporating recycled and recyclable materials into product packaging, DR.WU is committed to aligning all business operations with environmental, social, and governance (ESG) principles.
Strategy 5: AI Integration (AI-Enhanced DR.WU)
"I come from a science and engineering background. Back in 1996, during my second year of university, I registered WWW.DRWU.COM, even before the DR.WU brand existed," Wu recalled.
The website, originally created as part of his vision for telemedicine, remains DR.WU's official website today.
With major advances in technology, Wu now has a new ambition: transforming DR.WU into a virtual AI-powered platform.
Wu explained that everyone's skin condition is different, making personalized medical skincare solutions a key opportunity for AI applications.
Although DR.WU is an established skincare brand, the company has accumulated hundreds of thousands of skin-related data records.
Through big data analysis, Wu hopes to transform DR.WU from a business centered on people, brands, and products into an AI-powered platform.
While this vision may not be achievable in the short term, Wu emphasized that it remains a major direction for the company's future development.
Strong Financial Performance with an Average Dividend Payout Ratio of 90%
Wu described himself as a "highly pragmatic Taurus."
A review of DR.WU's recent financial statements reveals the company's strong financial position as an independent medical skincare brand.
In recent years, DR.WU has maintained an average dividend payout ratio of approximately 90%, gross profit margins above 70%, and operating profit margins of around 40%.
Wu explained that DR.WU has grown alongside its retail distribution channels and understands how to manage channel-related costs, giving the company a competitive advantage.
When asked whether he was overly frugal, Wu simply replied, "I'm pragmatic."
Wu emphasized that building a brand requires patience and long-term commitment.
"I have never focused on chasing sales figures. What matters is whether we are doing the right things and moving in the right direction," he said.
This approach helped DR.WU remain relatively resilient during the COVID-19 pandemic, while many competitors in the medical skincare industry suffered significant setbacks.
"The strength DR.WU has built over the decades comes from the legacy my father passed down to me. It is also the belief I have always upheld," Wu concluded.
